These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1482812)

  • 1. Hirudins: antithrombin anticoagulants.
    Stringer KA; Lindenfeld J
    Ann Pharmacother; 1992 Dec; 26(12):1535-40. PubMed ID: 1482812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirudin as alternative anticoagulant--a historical review.
    Markwardt F
    Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hirudin: the famous anticoagulant agent.
    Markwardt F
    Adv Exp Med Biol; 1993; 340():191-211. PubMed ID: 8154337
    [No Abstract]   [Full Text] [Related]  

  • 4. The anticoagulant and antithrombotic properties of hirudins.
    Märki WE; Wallis RB
    Thromb Haemost; 1990 Nov; 64(3):344-8. PubMed ID: 2096484
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lepirudin for heparin-induced thrombocytopenia.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):94-5. PubMed ID: 9774965
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and clinical use of bivalirudin.
    Sciulli TM; Mauro VF
    Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
    Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
    Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis.
    Sun Y; Wang B; Pei J; Luo Y; Yuan N; Xiao Z; Wu H; Luo C; Wang J; Wei S; Pei Y; Fu S; Wang D
    Br J Pharmacol; 2022 Jul; 179(14):3740-3753. PubMed ID: 35135035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of hirudin as an antithrombotic drug.
    Markwardt F
    Thromb Res; 1994 Apr; 74(1):1-23. PubMed ID: 8029805
    [No Abstract]   [Full Text] [Related]  

  • 13. Hirudin in renal insufficiency.
    Fischer KG
    Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
    Callas D; Fareed J
    Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin].
    Schiele F; Vuillemenot A; Mouhat T; Kieffer Y; Anguenot T; Bernard Y; Bassand JP
    Presse Med; 1996 May 4-11; 25(16):757-60. PubMed ID: 8692751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comeback of hirudin--an old-established anticoagulant agent.
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):10-23. PubMed ID: 2459000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In AT-III deficiency: heparin or hirudin?].
    Spannagel U
    MMW Fortschr Med; 1999 Oct; 141(42):14. PubMed ID: 10912097
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
    Callas DD; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.